Premium
[DT‐01–03]: CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA
Author(s) -
Ovod Vitaliy,
Bollinger James G.,
Mawuenyega Kwasi G.,
Hicks Terry J.,
Schneider Theresa,
Kasten Tom,
Sigurdson Wendy,
Sullivan Melissa,
Donahue Tamara A.,
Ramsey Kara,
Paumier Katrina L.,
Holtzman David M.,
Morris John C.,
Benzinger Tammie L.S.,
Fagan Anne M.,
Patterson Bruce W.,
Bateman Randall J.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.08.005
Subject(s) - biomarker , positron emission tomography , medicine , cerebrospinal fluid , amyloid (mycology) , amyloid beta , amyloidosis , pathology , chemistry , nuclear medicine , disease , biochemistry
N 164 70 110 158 Age 66 (68) 66 (67) 67 (68) 61 (68) Sex (female) 77 (47%) 21 (30%) 37 (34%) 61 (39%) MMSE 22 (64) 24 (64) 27 (62) 28 (63) APOE, E4 carrier 95 (59%) 23 (34%) 42 (48%) 58 (38%) [18]FBB, positive 128 (78%) 23 (33%) 53 (48%) 35 (22%) Change in etiological diagnosis 36 (22%) 14 (20%) 37 (35%) 36 (23%) Pre-PET diagnostic confidence (%) 82% (611) 77% (612) 72% (614) 85% (611) Post-PET diagnostic confidence (%) 92% (612) 86% (612) 86% (615) 91% (610) d Diagnostic confidence (%) 10 (615) 9% (614) 14% (618) 7% (613) Change in patient management 60 (37%) 13 (19%) 37 (35%) 21 (13%)